10 Key ASCO 2014 Presentations in Lung Cancer
Best of ASCO Metastatic Non-Small Cell Lung Cancer
50 Shades of Cancer Progression: The Continuum of Progression & How We Decide When to Change Treatment
Treating Invisible Disease: How the Probability of Disease We Can't See Changes Our Treatment Strategy in Lung Cancer
West Immunotherapy, Vaccines for Lung Cancer Mage-A3, Stimuvax, and Lucanix
West xcenda molec testing sf oct 2011 revised final
What is the value of maintenance therapy in advanced NSCLC, and who should get it?
Inherited T790M EGFR Mutation and Lung Cancer Risk
Changes Afoot: Changing Relationships between Engaged Patients and Docs in Cancer Care
Patient and doc engagement online west
Acquired Resistance to Targeted Therapy in EGFR and ALK-Positive Lung Cancer: New Ideas, New Agents
West egfr mutation acquired resistance
Core Principles of Managing Locally Advanced Non-Small Cell Lung Cancer
Key Clinical Implications of how a Cancer Evolves
West asco clin mgmt acquired resistance tk is
Dr. Jack West Oncology 2.0, to WA AG's Office
Transitioning Survival from Months to Years in Advanced Non-Small Cell Lung Cancer
Acquired resistance to EGFR TKIs in Lung Cancer (NSCLC)
Moving Beyond the Hype: 3 Key Steps for Personalized Cancer Medicine
Top 5 highlights in lung cancer, 2014
